EDGAR·FLOW

Retension Pharmaceuticals, Inc. — Form 10-Q

Filed November 18, 2026 · analyzed by the Periodic Agent
10-Q — Neutral significance 8/100
What the filing says
Eric Keller (CEO) and Alex Schwartz (CFO) signed routine Sarbanes-Oxley Sections 302 and 906 certifications on November 18, 2026, attesting to the accuracy of Retension Pharmaceuticals' Q3 2026 10-Q and the effectiveness of disclosure controls and internal financial reporting. No material weaknesses, deficiencies, or fraud disclosures were noted in the certifications.
Why this rating

Boilerplate executive certification exhibits; absence of internal control warnings is mildly positive but routine for compliant filers.

View original filing on SEC.gov ↗ RTSN · stock on Yahoo Finance ↗

See more from November 18, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.